SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH M impact

FDA Approves Livsayis as First siRNA Therapy for Generalized Myasthenia Gravis

The FDA approved Livsayis (cemdisiran), described as the first and only siRNA therapy for generalized myasthenia gravis and the only treatment with subcutaneous dosing four times a year.

REGN

Story updates

11:03:48 PM UTC
SquawkNews
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control tha

Related stories